» Articles » PMID: 36693954

Revealing Charge Heterogeneity of Stressed Trastuzumab at the Subunit Level

Overview
Specialty Chemistry
Date 2023 Jan 24
PMID 36693954
Authors
Affiliations
Soon will be listed here.
Abstract

Trastuzumab is known to be heterogeneous in terms of charge. Stressing trastuzumab under physiological conditions (pH 7.4 and 37 °C) increases charge heterogeneity further. Separation of charge variants of stressed trastuzumab at the intact protein level is challenging due to increasing complexity making it difficult to obtain pure charge variants for further characterization. Here we report an approach for revealing charge heterogeneity of stressed trastuzumab at the subunit level by pH gradient cation-exchange chromatography. Trastuzumab subunits were generated after limited proteolytic cleavage with papain, IdeS, and GingisKHAN®. The basic pI of Fab and F(ab) fragments allowed to use the same pH gradient for intact protein and subunit level analysis. Baseline separation of Fab subunits was obtained after GingisKHAN® and papain digestion and the corresponding modifications were determined by LC-MS/MS peptide mapping and middle-down MALDI-ISD FT-ICR MS. The described approach allows a comprehensive charge variant analysis of therapeutic antibodies that have two or more modification sites in the Fab region.

References
1.
Liu H, Ponniah G, Zhang H, Nowak C, Neill A, Gonzalez-Lopez N . In vitro and in vivo modifications of recombinant and human IgG antibodies. MAbs. 2014; 6(5):1145-54. PMC: 4622420. DOI: 10.4161/mabs.29883. View

2.
Cymer F, Beck H, Rohde A, Reusch D . Therapeutic monoclonal antibody N-glycosylation - Structure, function and therapeutic potential. Biologicals. 2017; 52:1-11. DOI: 10.1016/j.biologicals.2017.11.001. View

3.
Wagner-Rousset E, Fekete S, Morel-Chevillet L, Colas O, Corvaia N, Cianferani S . Development of a fast workflow to screen the charge variants of therapeutic antibodies. J Chromatogr A. 2017; 1498:147-154. DOI: 10.1016/j.chroma.2017.02.065. View

4.
Haberger M, Bomans K, Diepold K, Hook M, Gassner J, Schlothauer T . Assessment of chemical modifications of sites in the CDRs of recombinant antibodies: Susceptibility vs. functionality of critical quality attributes. MAbs. 2014; 6(2):327-39. PMC: 3984323. DOI: 10.4161/mabs.27876. View

5.
Nowak C, Cheung J, M Dellatore S, Katiyar A, Bhat R, Sun J . Forced degradation of recombinant monoclonal antibodies: A practical guide. MAbs. 2017; 9(8):1217-1230. PMC: 5680805. DOI: 10.1080/19420862.2017.1368602. View